Synthesis and biological activity of AM-112 and related oxapenem analogues

Journal of Antibiotics

Volumn 56, Issue 10, 2003, Pages 838-847

  Simpson, Iain ^a   Urch, Christopher J ^b   Hagen, Gudrun ^c   Albrecht, Ralf ^c   Sprinkart, Birgit ^c   Pfaendler, Hans R ^c  

^a Micron Research Ltd   (United Kingdom)

^b Amura Therapeutics Ltd   (United Kingdom)

^c UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

2 (4 AMMONIO 1,1 DIMETHYLBUTYL) 6 (1' HYDROXYETHYL)OXAPENEM 3 CARBOXYLATE; 3 (4 AMINO 1,1 DIMETHYLBUTYL) 6 (1 HYDROXYETHYL)OXAPENEM 3 CARBOXYLIC ACID; AM 113; AM 114; AM 115; AM 116; AM 117; AM 118; AM 119; AM 120; AM 121; AM 122; AM 126; AM 133; AM 143; AM 144; AM 145; AM 146; AM 147; AM 148; AM 149; AM 150; AM 151; AM 152; AM 154; AM 155; ANTIBIOTIC AGENT; BETA LACTAMASE INHIBITOR; CEFTAZIDIME; OXAPENEM DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIUM ISOLATE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG POTENTIATION; DRUG SCREENING; DRUG STABILITY; DRUG SYNTHESIS; ENTEROCOCCUS; ENZYME INHIBITION; ENZYME SYNTHESIS; GRAM NEGATIVE BACTERIUM; NONHUMAN; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS; STEREOCHEMISTRY;

EID: 0242523926     PISSN: 00218820     EISSN: None     Source Type: Journal    
DOI: 10.7164/antibiotics.56.838     Document Type: Article

References (20)

1. Livermore, D. M.: β-Lactamases in laboratory and clinical resistance. Clin. Microbiol. Rev. 8: 557-584, 1995
2. Bradford, P. A.: Extended-spectrum β-lactamases in the 21st century: characterisation, epidemiology, and detection of this important resistance threat. Clin. Microbiol. Rev. 14: 933-951, 2001
3. Maiti, S. N.; O. A. Phillips, R. G. Micetich & D. M. Livermore: β-Lactamase inhibitors: agents to overcome bacterial resistance. Curr. Med. Chem. 5: 441-456, 1998
4. Cherry, P. C.; C. E. Newall & N. S. Watson: Preparation of the 7-oxo-4-oxa-1-azabicyclo[3.2.0]hept-2-ene system and the reversible cleavage of its oxazoline ring. J. Chem. Soc., Chem. Commun. 1978: 469-470, 1978
5. Murakami, M.; T. Aoki, M. Matsuura & W. Nagata: Synthesis and biological properties of 1-oxapenems. J. Antibiotics 43: 1441-1449, 1990
6. Pfaendler, H. R.; W. Hendel & U. Nagel: Stable oxapenem-3-carboxylic acids-a new class of β-lactam antibiotics. Influence of 2- and 6-alkyl substituents. Z. Naturforsch., B: Chem. Sci. 47: 1037-1049, 1992
7. Pfaendler, H. R.; F. Weisner & K. Metzger: Synthesis and antibacterial activity of (1′R,5R,6R)-2-tert-butyl-6-(1′-hydroxyethyl oxapenem-3-carboxylic acid. Bioorg. Med. Chem. Lett. 3: 2211-2218, 1993
8. Livermore, D. M.; L. Tysall, M. Warner & I. N. Simpson: Oxapenem analogues as antibiotics and broad spectrum β-lactamase inhibitors. Abstracts of the 41st Intersci. Conf. on Antimicrob. Agents Chemother., September and December 2001, page 212
9. Jamieson, C. E.; P. A. Lambert & I. N. Simpson: Protection of ceftazidime against class A and class C β-lactamases by oxapenems. Abstracts of the 41st Intersci. Conf. on Antimicrob. Agents Chemother., September and December 2001, page 213
10. Simpson I. N.; E. Di Modugno, D. Jabes & D. Nicolau: Oxapenem AM-112: in vivo efficacy alone and in combination with ceftazidime in animal models of infection, involving pathogens producing class A and class C β-lactamases. Abstracts of the 41st Intersci. Conf. on Antimicrob. Agents Chemother., September and December 2001, page 213
11. White L. O.; L. Brevik, R. Owens, I. Simpson, M. Cavaleri & D. Jabes: AM-112, a novel enhanced-spectrum oxapenem β-lactamase inhibitor: oral and parental pharmacokinetics (pk), with and without ceftazidime (TAZ), in rats and mice. Abstracts of the 41st Intersci. Conf. on Antimicrob. Agents Chemother., September and December 2001, page 213
12. Simpson I. N.; C. J. Urch, D. M. Livermore, C. Brunati, M. Cavaleri & L. O. White: Broad-spectrum β-lactamase inhibitor AM-112: Synthesis and enhancement of the in vitro activity of ceftazidime and piperacillin. Abstracts of the 42nd Intersci. Conf. on Antimicrob. Agents Chemother., September 2002, page 177
13. Pfaendler, H. R.; T. Neumann & R. Bartsch: Synthesis and biological activity of enantiomeric oxapenemcarboxylic acids. Synthesis. 11: 1179-1184, 1992
14. Pfaendler, H. R. & W. Hendel: Preparation of stable oxapenemcarboxylates as antibacterial agents. EP 301 394, July 20, 1988
15. Pfaendler, H. R.; K. G. Metzger, R. Endermann, I. Haller, H. Wild & W Hartwig: Preparation and formulation of oxapenemcarboxylates a β-lactamase inhibitors. EP 362 622, September 21, 1989
16. Pfaendler, H. R.: Preparation of 6-[(1S)-1-hydroxyalkyl]oxapenem-3-carboylic acids and their use as β-lactamase inhibitors. EP 548 790, December 17, 1992
17. Pfaendler, H. R. & I. N. Simpson: Pharmaceutical compositions containing oxapenem-3-carboxylic acids. WO 02/32423, October 11, 2001
18. O'Callaghan, C. H.; P. W. Muggleton & G. W. Ross: Effects of β-lactamase from gram-negative organisms on cephalosporins and penicillins. Antimicrob. Agents Chemother. 8: 57-63, 1968
19. Simpson, I. N.; S. J. Plested, M. J. Budin-Jones, J. Lees, R. W. Hedges & G. A. Jacoby: Characterization of a novel plasmid-mediated β-lactamase and its contribution to β-lactam resistance in Pseudomonas aeruginosa. FEMS Microbiol. Lett. 19: 23-27, 1983
20. Matthew, M.; A. M. Harris, M. J. Marshall & G. W. Ross: Use of analytical isoelectric focusing for detection and identification of β-lactamases. J. Gen. Microbiol. 88: 169-178, 1975